UK NICE rejects Daiichi Sankyo’s Enhertu for breast cancer
07 Mar 2024
Drug Approval
Preview
Source: Pharmaceutical Technology
Draft guidance published in September 2023 did not recommend Enhertu for breast cancer patients post-chemotherapy. Credit: ORION PRODUCTION / Shutterstock.com.
The UK National Institute for Health and Care Excellence (Nice) has declined to recommend Daiichi Sankyo‘s Enhertu (trastuzumab deruxtecan) for the treatment of advanced HER2-low breast cancer in adults.
The final draft guidance comes after unsuccessful negotiations between National Health Service (NHS) England and Daiichi Sankyo to reach a cost-effective commercial deal to offer the therapy for NHS use.
The appraisal of Enhertu by NICE had been on hold since December 2023 while discussions were underway.
Draft guidance published in September had already set a precedent by not recommending Enhertu for patients post-chemotherapy, citing uncertainties in the data and cost-effectiveness that exceeded the institute’s acceptable range for NHS resource use.
Approximately 1000 individuals would have been eligible for treatment with Enhertu if recommended.
See Also:
MorphoSys files patent for antibodies for treating inflammatory, autoimmune diseases, or cancer
Preview
Source: Pharmaceutical Technology
Kura Oncology files patent for combination treatment for head and neck cancer
Preview
Source: Pharmaceutical Technology
Registered consultees, including Daiichi Sankyo and patient carer groups, can appeal against the final draft recommendations.
NICE maintains its position of not endorsing Enhertu for NHS use without a commercial arrangement that leads to a cost-effective price.
NICE medicines evaluation director Helen Knight stated: “We are extremely disappointed not to be able to recommend Enhertu for use in the NHS for advanced HER2-low breast cancer.
“The backdrop to the commercial discussions was the independent appraisal committee’s belief that, based on the available evidence, Enhertu represents a significant development for people with HER2-low advanced breast cancerHER2-low advanced breast cancer who currently have limited chemotherapy options. Most have no targeted treatments available to them.
“However, a key uncertainty in estimating Enhertu’s cost-effectiveness was how much longer people on Enhertu live compared with those receiving standard treatment in the future. The independent committee carefully considered all the evidence and applied its judgement on the most clinically plausible approach on which to base its decision.”
The latest development comes after NICE recommended Pfizer‘s ritlecitinib as a new treatment option for severe hair loss associated with alopecia areata.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.